Biotech stocks jump on AbbVie deal to buy cancer drugmaker ImmunoGen for $10 billion

Other biotech companies developing ADCs, which are among the hottest areas in the pharmaceutical industry, jumped on the news of AbbVie's buyout of ImmunoGen. 

from Health and Science https://ift.tt/vn93R4p
https://ift.tt/Aac3zd5
https://ift.tt/937yHq0